Health Technology, Healthcare Analytics
businesswire | July 28, 2023
AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q2 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive resource on new, pending and projected Specialty and Rare Disease drug launches, and cell and gene therapies, biosimilars and generics. This complimentary, valuable source of industry information supports the specialty drug market needs of stakeholders and decision-makers including pharmaceutical manufacturers, payers and providers, with essential updates on products that are making an impact for millions of individuals living with or affected by rare disease or complex chronic conditions.
“As an industry-leading, global healthcare and specialty pharmacy solutions organization, my team researched, annotated and compiled these critically important updates, timely information, statistics and facts to support our clients and partners and other industry stakeholders,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth.
Dea Belazi, president & CEO, AscellaHealth, adds, “We are proud to empower all market stakeholders with key data and insights that guide the industry. The dedicated work of pharmaceutical manufacturers to launch innovative therapies complemented by the efforts of payers and providers to ensure affordability and treatment availability are so commendable.”
AscellaHealth provides end-to-end, customized solutions to all industry stakeholders, namely patients, life sciences manufacturers, payers and providers to improve medication access, optimize clinical outcomes and enhance the patient journey. Services include:
Pre-Commercialization & Market Access
Exclusive Distribution, Wholesale, and 3PL Services
International Specialty Pharmacy Fulfillment including Limited Distribution Drugs
Comprehensive HUB and Patient Support Services
Custom Compliance and Persistency Programs
Streamlined Prior Authorizations
Technology-based Patient Engagement
Integrated Copay and Financial Assistance Programs
Real-time Rx Data and Analytics
Specialty Pharmacy & Medical Benefit Management
About AscellaHealth LLC
AscellaHealth, a global Healthcare & Specialty Pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, and a NASP Strategic Channel Partner of the Year award winner, AscellaHealth’s best-in-class, patient-centric approach is built upon proprietary technology processes for novel programs and services to support the launch of specialty medications and proactively address multiple challenges, optimize clinical health outcomes, and improve quality of life for this patient population.
Read More
Health Technology, AI
PRNewswire | July 21, 2023
WELL Health Technologies Corp. a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that as of July 19, 2023 it has entered into an agreement to acquire clinic assets form MCI Medical clinics Inc., a subsidiary of MCI Onehealth Technologies Inc. (TSX: DRDR) ("MCI") and a subscription agreement for a convertible debenture financing in MCI which will strategically focus the MCI business around its leading AI, Data Science and Rare & Complex Disease Detection platform (the "Transaction").
"This is a major step for WELL and it's all about the power of Artificial Intelligence and how it can help solve some of the most difficult disease detection and diagnosis problems healthcare providers and patients face every day", said Hamed Shahbazi, Founder and CEO of WELL Health. "We're thrilled to enter into a number of agreements that result in a strategic alliance that will immediately position MCI OneHealth as a key national leader in the multi-billion dollar disease detection marketplace."
Dr. Michael Frankel, Chief Medical Officer of WELL commented, "MCI's platform has already saved lives by discovering those 'needle in a haystack cases' and delivered value to hundreds of healthcare providers. As a physician I am excited to work with them to evolve their platform and help them expand their pool of participating physicians. I am also very excited to welcome the talented clinical staff of the clinics that will be joining the WELL Family."
As part of the Transaction, WELL will acquire a significant portion of MCI's clinical assets, which are located in Southern Ontario and offer a range of primary care services, including family medicine, women's health, and other specialties. The acquisition brings more than 130 physicians to the WELL family, adding to over 3,000 providers in WELL's patient services business units across North America. The MCI clinics will be integrated with WELL's Ontario based clinic chain which is the largest owned and operated network of clinics in the province. WELL's Ontario clinics offer a breadth of care including primary care, diagnostics, allied health, and other medical subspecialties. The acquisition of these well-known and regarded primary care clinics in Ontario marks a significant milestone in WELL's national clinic expansion strategy. The clinics in this acquisition are expected to collectively contribute more than $21 million of annual revenue and are expected to contribute positive Adjusted EBITDA in 2024. Following the completion of the Transaction, WELL plans to integrate leading edge software and workflows, such as OceanMD's patient engagement tools, DoctorCare's RCM services, and WELL AI Voice, from its Practitioner Enablement Platform.
WELL is also advancing a short-term bridge loan to MCI designed to ensure the company has the required resources to operate until the various transactions close. It is anticipated that closing shall occur on or around Oct 1, 2023. Once the Transaction closes, WELL will also have representation on MCI's board of directors.
Upon closing of the Transaction, WELL will be a holder of MCI's convertible debentures, and shall subject to the satisfaction of certain conditions, have certain rights associated with call options granted by two shareholders of MCI for up to 30.8 million Class A Subordinate Voting Shares and 30.8 million Class B Multiple Voting shares of MCI's go-forward business. MCI plans to utilize the proceeds from this convertible debenture financing to advance their technology-enabled healthcare research offerings, placing a strong emphasis on harnessing the power of artificial intelligence for healthcare applications.
This investment will be part of WELL's AI Investment Program1 where WELL stated that it will make meaningful investments in AI focused companies to help improve tools for providers and their patients. WELL is confident that our work in AI will meaningfully enhance our ESG goals and deliver societal value.
Eight Capital acted as financial advisor to WELL Health in connection with the Transaction, and Clark Wilson acted as WELL Health's legal counsel.
About WELL Health Technologies Corp.
WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 28,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 130 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF".
Read More
Digital Healthcare, Medical Devices
Businesswire | April 12, 2023
Pria, an innovative healthcare technology company that is transforming the way chronic care management is delivered at home, announced that Pria will be using InterSystems Health Connect Cloud to deliver the integration required to accelerate Pria’s efforts to revolutionize the operating system for health at home.
With Pria, providers, patients, and family caregivers can access a suite of health management tools to help them monitor and manage all aspects of their prescribed care plans. Through cloud-based connectivity, Pria’s platform can be used to identify eligible patients, align their care plan with a Pria Wellness Plan, and integrate patient data with their electronic health records.
With guaranteed delivery, reliability, and stability, InterSystems Health Connect Cloud delivers comprehensive healthcare interoperability via a platform-as-a-service (PaaS) offering. Health Connect Cloud streamlines data integration between clinical systems and applications, while managing the entire infrastructure and providing enhanced data automation and management capabilities to help providers and application developers rapidly leverage HL7 FHIR® and other healthcare standards to connect systems and solutions. As a PaaS model, it is ideal for digital health solution developers such as Pria because it reduces infrastructure and licensing costs and ensures compliance with standards, allowing developers to focus on building their unique product offering.
According to Pria’s CEO Ainar Abdrakhmanov, “We are thrilled with the continued support and collaboration from InterSystems to advance our operating system for health at home. With InterSystems' cutting-edge technology and expertise, we will develop a platform that enables healthcare organizations to deliver health-at-home, value-based care for the Medicare population. Our innovative platform will simplify and improve the scalability of the health-at-home solutions market, thereby resolving current market pain points.”
“InterSystems is thrilled to collaborate with forward-thinking companies in pursuit of a shared goal: leveraging technology to deliver advanced data automation and intelligence solutions that improve patient outcomes,” said Paul Grabscheid, Vice President of Strategic Planning, InterSystems. “Through supporting innovative companies like Pria, we are excited to push the boundaries of what's possible in healthcare and revolutionize traditional approaches to data management and analysis.”
Pria is building the standard for health-at-home solutions by delivering a platform that streamlines workflows, improves patient outcomes, and reduces costs. The company's innovative approach has earned it a reputation as a game-changer in the healthcare industry. Pria's integration of health-at-home solutions on one platform supports healthcare organizations to lower costs while delivering a patient engagement experience through Pria's Digital Nurse.
Pria will be demonstrating their operating system for health at home and the Pria Digital Nurse at HIMSS 2023 in InterSystems booth #942.
Pria also announced an investment from InterSystems Corporation, that follows several years of technical collaboration and promises to accelerate Pria’s efforts to revolutionize the operating system for health at home.
About InterSystems
Established in 1978, InterSystems is the leading provider of next-generation solutions for enterprise digital transformations in the healthcare, finance, manufacturing, and supply chain sectors. Its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. InterSystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 36 offices in 25 countries worldwide.
Read More